Tag Archives: Onyx Pharmaceuticals

Onyx Bullish in 2012 Outlook

With an all-important FDA decision on carfilzomib scheduled for July 27, Onyx hopes to graduate to the next stage of commercial success. For a feature-length profile of Onyx and CEO Tony Coles, click here. Following on a strong 4Q report, Onyx Pharmaceuticals’ CEO Tony Coles said the company hopes to transform itself from a one-product […]
Posted in FDA, Market Access, People, pricing, R&D, Regulatory, Strategy | Also tagged , , | Leave a comment
  • Categories

  • Meta